In the third quarter, Altria continued to balance maximizing profitability from our core tobacco businesses with investing to realize a vision of responsibly leading the transition of adult smokers to a smoke-free future.
We're disappointed in this decision as IQOS is the only inhalable tobacco product to have received FDA authorization as a modified risk tobacco product.
We remain committed to the heated tobacco category and believe it can play an important role in transitioning smokers to a smoke-free future.
For the first nine months of the year, adjusted earnings per share grew 4.5%, primarily driven by the strong financial performance of our tobacco businesses and higher ABI adjusted earnings.
Oral tobacco products segment retail share for the third quarter was sequentially unchanged as strong share gains for on!
Total reported oral tobacco products segment volume decreased by 3.8% for the third quarter and by 0.5% for the first nine months.
